Literature DB >> 11063606

3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.

P Ducrot1, M Legraverend, D S Grierson.   

Abstract

Several series of cyclin-dependent kinase inhibitors previously prepared in our laboratory were compared using 3D-QSAR (CDK1) and docking (CDK2) techniques. Evaluation of our own library of 93 purine derivatives served to establish the model which was validated by evaluation of an external library of 71 compounds. The best predictions were obtained with the CoMFA standard model (q(2) = 0.68, r(2) = 0.90) and with the CoMSIA combined steric, electrostatic, and lipophilic fields (q(2) = 0.74, r(2) = 0.90). The CDK1 3D-QSAR model was then superimposed to the ATP/CDK2 binding site, giving direct contour maps of the different fields. Although too few compounds were evaluated on CDK5 to derive a 3D-QSAR model, some interesting SARs have been deduced. Comparison of the results obtained from both methods helped with understanding the specific activity of some compounds and designing new specific CDK inhibitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063606     DOI: 10.1021/jm000965t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Effect of steric molecular field settings on CoMFA predictivity.

Authors:  Ruchi R Mittal; Ross A McKinnon; Michael J Sorich
Journal:  J Mol Model       Date:  2007-11-24       Impact factor: 1.810

2.  Transferable scoring function based on semiempirical quantum mechanical PM6-DH2 method: CDK2 with 15 structurally diverse inhibitors.

Authors:  Petr Dobeš; Jindřich Fanfrlík; Jan Rezáč; Michal Otyepka; Pavel Hobza
Journal:  J Comput Aided Mol Des       Date:  2011-02-01       Impact factor: 3.686

3.  Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery.

Authors:  Jiansong Fang; Ranyao Yang; Li Gao; Shengqian Yang; Xiaocong Pang; Chao Li; Yangyang He; Ai-Lin Liu; Guan-Hua Du
Journal:  Mol Divers       Date:  2014-12-16       Impact factor: 2.943

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.